These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34416511)

  • 1. New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications.
    Cristina Mendonça Nogueira T; Vinicius Nora de Souza M
    Bioorg Med Chem; 2021 Sep; 46():116340. PubMed ID: 34416511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule anticancer drugs approved during 2021-2022: Synthesis and clinical applications.
    Tamatam R; Mohammed A
    Eur J Med Chem; 2024 Jun; 272():116441. PubMed ID: 38759455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis.
    Ayala-Aguilera CC; Valero T; Lorente-Macías Á; Baillache DJ; Croke S; Unciti-Broceta A
    J Med Chem; 2022 Jan; 65(2):1047-1131. PubMed ID: 34624192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
    Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S
    Signal Transduct Target Ther; 2021 May; 6(1):201. PubMed ID: 34054126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.
    Torre BG; Albericio F
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the translational value of pre-clinical studies for clinical response rate in oncology: an exploratory investigation of 42 FDA-approved small-molecule targeted anticancer drugs.
    Liu WA; Yu L; Morcos PN; Mercier F; Brennan BJ
    Cancer Chemother Pharmacol; 2020 Jun; 85(6):1015-1027. PubMed ID: 32424570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects.
    Bai YR; Seng DJ; Xu Y; Zhang YD; Zhou WJ; Jia YY; Song J; He ZX; Liu HM; Yuan S
    Eur J Med Chem; 2024 Oct; 276():116706. PubMed ID: 39053188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An empirical analysis of overall survival in drug approvals by the US FDA (2006-2023).
    Elbaz J; Haslam A; Prasad V
    Cancer Med; 2024 Apr; 13(8):e7190. PubMed ID: 38659418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in the approval of cancer therapies by the FDA in the twenty-first century.
    Scott EC; Baines AC; Gong Y; Moore R; Pamuk GE; Saber H; Subedee A; Thompson MD; Xiao W; Pazdur R; Rao VA; Schneider J; Beaver JA
    Nat Rev Drug Discov; 2023 Aug; 22(8):625-640. PubMed ID: 37344568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The response rate of alternative treatments for drugs approved on the basis of response rate.
    Haslam A; Gill J; Prasad V
    Int J Cancer; 2021 Feb; 148(3):713-722. PubMed ID: 32700797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug approvals for 2020: Synthesis and clinical applications.
    Yuan S; Luo YQ; Zuo JH; Liu H; Li F; Yu B
    Eur J Med Chem; 2021 Apr; 215():113284. PubMed ID: 33611190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. U.S. Food and Drug Administration: Initial Experience with the Real-Time Oncology Review Program.
    de Claro RA; Gao JJ; Kim T; Kluetz PG; Theoret MR; Beaver JA; Pazdur R
    Clin Cancer Res; 2021 Jan; 27(1):11-14. PubMed ID: 32816899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncology's trial and error: Analysis of the FDA withdrawn accelerated approvals.
    Preziosi AJ; Priefer R
    Life Sci; 2024 Jun; 346():122615. PubMed ID: 38582392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
    Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
    Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New drug approvals for 2021: Synthesis and clinical applications.
    Yuan S; Wang DS; Liu H; Zhang SN; Yang WG; Lv M; Zhou YX; Zhang SY; Song J; Liu HM
    Eur J Med Chem; 2023 Jan; 245(Pt 1):114898. PubMed ID: 36370552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
    Kandemir EA
    J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.
    Sochacka-Ćwikła A; Mączyński M; Regiec A
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.